Recent Publications

Search for any of these articles on PubMed

Molecular Theraputics Research Program investigators are indicated in bold; co-authors who are primary members of other Norris Cotton Cancer Center Research Programs are indicated in bold italics.

*Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA (2007, In press). Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat.

Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M (2006). Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther 5(5):1108-1116.

*Armand R, Channon JY, Kintner J, White KA, Miselis KA, Perez RP, Lewis LD (2004). The effects of ethidium bromide induced loss of mitochondrial DNA on mitochondrial phenotype and ultrastructure in a human leukemia T-cell line (MOLT-4 cells). Toxicol Appl Pharmacol 196(1):68-79.

Arnold NB, Arkus N, Gunn J, Korc M (2007). The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13(1):18-26.

Arnold NB, Korc M (2005). SMAD7 abrogates TGF-beta 1 mediated growth inhibition in colo-357 cells through functional inactivation of the retinoblastoma protein. J Biol Chem 280(23):21858-21866.

*Ashamalla H, Zaki B, Mokhtar B, Lewis L, Lavaf A, Nasr H, Colella F, Dosik D, Krishnamurthy M, Saad N, Guriguis A (2007). Fractionated stereotactic radiotherapy boost and weekly Paclitaxel in malignant gliomas clinical and pharmacokinetics results. Technol Cancer Res Treat 6(3):169-176.

Boyer Arnold N, Korc M (2005). Smad7 abrogates transforming growth factor-{beta}1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein. J Biol Chem 280(23):21858-21866.

Brown DJ, Rzucidlo EM, Merenick BL, Wagner RJ, Martin KA, Powell RJ (2005). Endothelial cell activation of the smooth muscle cell phosphoinositide 3-kinase/Akt pathway promotes differentiation. J Vasc Surg 41(3):509-516.

Burke LP, Lewis LD, Perez RP (2003). Ubiquinone does not rescue acute myeloid leukemia cells from growth inhibition by statins. Leukemia 17(1):267-268.

*Carpenter CM, Pogue BW, Jiang S, Dehghani H, Wang X, Paulsen KD, Wells WA, Forero J, Kogel C, Weaver JB, Poplack SP, Kaufman PA (2007). Image-guided optical spectroscopy provides molecular-specific information in vivo: MRI-guided spectroscopy of breast cancer hemoglobin, water, and scatterer size. Opt Lett 32(8):933-935.

Carriere C, Seeley ES, Goetze T, Longnecker DS, Korc M (2007). The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A 104(11):4437-4442.

Caserta TM, Kommagani R, Yuan Z, Robbins DJ, Mercer CA, Kadakia MP (2006). p63 Overexpression Induces the Expression of Sonic Hedgehog. Mol Cancer Res 4(10):759-768.
Chatfield K, Eastman A (2004). Inhibitors of protein phosphatases 1 and 2A differentially prevent intrinsic and extrinsic apoptosis pathways. Biochem Biophys Res Commun 323(4):1313-1320.

*Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC (2004). The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 103(8):3158-3166.

*Couch RD, Browning RG, Honda T, Gribble GW, Wright DL, Sporn MB, Anderson AC (2005). Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: Implications for a molecular mechanism of action. Bioorg Med Chem Lett 15(9):2215-2219.

*Couch RD, Ganem NJ, Zhou M, Popov VM, Honda T, Veenstra TD, Sporn MB, Anderson AC (2006). 2-cyano-3,12-dioxooleana-1,9(11)-diene-28-oic acid disrupts microtubule polymerization: A possible mechanism contributing to apoptosis. Mol Pharmacol 69(4):1158-1165.

Curtin JC, Spinella MJ (2005). p53 in human embryonal carcinoma: Identification of a transferable, transcriptional repression domain in the N-terminal region of p53. Oncogene 24(9):1481-1490.

De Biasio A, Vrana JA, Zhou P, Qian L, Bieszczad CK, Braley KE, Domina AM, Weintraub SJ, Neveu JM, Lane WS, Craig RW (2007). N-terminal truncation of antiapoptotic MCL1, but not G2/M-induced phosphorylation, is associated with stabilization and abundant expression in tumor cells. J Biol Chem 282(33):23919-23936.

Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J (2006). Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12(4):389-396.

*Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, Talalay P (2005). Extremely potent triterpenoid inducers of the Phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 102(12):4584-4589.

Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW (2004). MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23(31):5301-5315.

Dragnev KH, Black CC, Rigas JR (2004). The role of docetaxel in resectable stage IIIA non-small cell lung cancer. Adv Lung Cancer 6:3-7.

*Dragnev KH, Feng Q, Ma Y, Shah SJ, Black C, Memoli V, Nugent W, Rigas JR, Kitareewan S, Freemantle S, Dmitrovsky E (2007). Uncovering novel targets for cancer chemoprevention. Recent Results Cancer Res 174:235-243.

*Dragnev KH, Petty WJ, Ma Y, Rigas JR, Dmitrovsky E (2005). Nonclassical retinoids and lung carcinogenesis. Clin Lung Cancer 6(4):237-244.

*Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E (2005). Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 23(34):8757-8764.

*Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E (2007). A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res 13(6):1794-1800.

Dufresne SD, Belloni DR, Levy NB, Tsongalis GJ (2007). Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL monitor assay. Arch Pathol Lab Med 131(6):947-950.

*Dufresne SD, Belloni DR, Wells WA, Tsongalis GJ (2006). BRCA1 and BRCA2 mutation screening using SmartCycler II high-resolution melt curve analysis. Arch Pathol Lab Med 130(2):185-187.

Eastman A (2004). Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 91(2):223-231.

Eastman A, Perez RP (2006). New targets and challenges in the molecular therapeutics of cancer. Br J Clin Pharmacol 62(1):5-14.

Eisenberg BL (2005). Soft tissue sarcomas: Opportunities for defining the molecular phenotype of a solid tumor malignancy. Curr Opin Oncol 17(4):355-356.

Eisenberg BL (2006). Combined-modality strategy for gastrointestinal stromal tumors. Semin Oncol 33 (6 Suppl 11):S75-S78 Review.

Eisenberg BL (2006). Combining imatinib with surgery in gastrointestinal stromal tumors: Rationale and ongoing trials. Clin Colorectal Cancer 6(Suppl 1):S24-S29.

*Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Pepin SE, Simmons NE (2004). Pituitary carcinomas respond to temozolomide. Neuro-Oncology 6:374.

*Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE (2006). Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105(4):621-626.

*Fava RA, Elliott S, Raymond L, Mollmark J, Hays E, Honda T, Gribble GW, Sporn MB, Vincenti MP (2007). The synthetic triterpenoid TP-222 inhibits RANKL stimulation of osteoclastogenesis and matrix metalloproteinase-9 expression. J Rheumatol 34(5):1058-1068.

Fetalvero KM, Shyu M, Nomikos AP, Chiu YF, Wagner RJ, Powell RJ, Hwa J, Martin KA (2006). The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol 290(4):H1337-H1346.

*Freemantle SJ, Spinella MJ, Dmitrovsky E (2003). Retinoids in cancer therapy and chemoprevention: Promise meets resistance. Oncogene 22(47):7305-7315.

*Freemantle SJ, Vaseva AV, Ewings KE, Bee T, Krizan KA, Kelley MR, Hattab EM, Memoli VA, Black CC, Spinella MJ, Dmitrovsky E (2007). Repression of cyclin D1 as a target for germ cell tumors. Int J Oncol 30(2):333-340.

Gauthier I, Ding K, Winton T, Shepherd FA, Livingston R, Johnson DH, Rigas JR, Whitehead M, Graham B, Seymour L (2007). Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience. Lung Cancer 55(3):357-363.

*Giuliano CJ, Kerley-Hamilton JS, Bee T, Freemantle SJ, Manickaratnam R, Dmitrovsky E, Spinella MJ (2005). Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta 1731(1):48-56.

Goetz JA, Singh S, Suber LM, Kull FJ, Robbins DJ (2006). A highly conserved amino-terminal region of sonic Hedgehog is required for the formation of its freely diffusible multimeric form. J Biol Chem 281(7):4087-4093.

Gridley S, Chavez JA, Lane WS, Lienhard GE (2006). Adipocytes contain a novel complex similar to the tuberous sclerosis complex. Cell Signal 18(10):1626-1632.
Guo J, Kleeff J, Zhao Y, Li J, Giese T, Esposito I, Buchler MW, Korc M, Friess H (2006). Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. Int J Mol Med 17(5):761-767.

*Heim KC, White KA, Deng D, Tomlinson CR, Moore JH, Freemantle SJ, Spinella MJ (2007). Selective repression of retinoic acid target genes by RIP140 during induced tumor cell differentiation of pluripotent human embryonal carcinoma cells. Mol Cancer 6(1):57.

Hirsh V, Desjardins P, Needles BM, Rigas JR, Jahanzeb M, Nguyen L, Zembryki D, Leopold LH (2007). Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. Am J Clin Oncol 30(3):245-251.

*Honda T, Favaloro FG, Jr, Janosik T, Honda Y, Suh N, Sporn MB, Gribble GW (2004). Efficient synthesis of (-) - and (+)-tricyclic compounds with enone functionalities in rings A and C: A novel class of orally active anti-inflammatory and cancer chemopreventive agents. Org Biomol Chem 1(24):4384-4391.

*Honda T, Janosik T, Honda Y, Han J, Liby KT, Williams CR, Couch RD, Anderson AC, Sporn MB, Gribble GW (2004). Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. J Med Chem 47(20):4923-4932.

*Honda T, Liby KT, Su X, Sundararajan C, Honda Y, Suh N, Risingsong R, Williams CR, Royce DB, Sporn MB, Gribble GW (2006). Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. Bioorg Med Chem Lett 16(24):6306-6309.

*Honda T, Sundararajan C, Yoshizawa H, Su X, Honda Y, Liby KT, Sporn MB, Gribble GW (2007). Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: Highly potent anti-inflammatory and cytoprotective agents. J Med Chem 50(8):1731-1734.

*Hsu M, Mabaera R, Lowrey CH, Martin DI, Fiering S (2007). CpG hypomethylation in a large domain encompassing the embryonic {beta}-like globin genes in primitive erythrocytes. Mol Cell Biol 27(13):5047-5054.

Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC (2005). Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 65(11):4799-4808.

*Ikeda T, Sporn M, Honda T, Gribble GW, Kufe D (2003). The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res 63(17):5551-5558.

Ishiwata T, Kudo M, Onda M, Fujii T, Teduka K, Suzuki T, Korc M, Naito Z (2006). Defined localization of nestin-expressing cells in L-arginine-induced acute pancreatitis. Pancreas 32(4):360-368.

Kayed H, Kleeff J, Kolb A, Ketterer K, Keleg S, Felix K, Giese T, Penzel R, Zentgraf H, Buchler MW, Korc M, Friess H (2006). FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int J Cancer 118(1):43-54.

Keegan BP, Akerman BL, Pequeux C, North WG (2006). Provasopressin expression by breast cancer cells: Implications for growth and novel treatment strategies. Breast Cancer Res Treat 95(3):265-277.

Keegan BP, Wells WA, Memoli VA, North WG (2007, In press). Detection of provasopressin in invasive and non-invasive (DCIS) human breast cancer using a monoclonal directed against the C-terminus (MAGI). Inter J Cancer.

Kerley-Hamilton JS, Pike AM, Hutchinson JA, Freemantle SJ, Spinella MJ (2007). The direct p53 target gene, FLJ11259/DRAM, is a member of a novel family of transmembrane proteins. Biochim Biophys Acta 1769(4):209-219.

*Kerley-Hamilton JS, Pike AM, Li N, DiRenzo J, Spinella MJ (2005). A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma. Oncogene 24(40):6090-6100.

Kim HT, Kim KP, Lledias F, Kisselev AF, Scaglione KM, Skowyra D, Gygi SP, Goldberg AL (2007). Certain E2-E3 pairs synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. J Biol Chem 282(24):17375-17386.

*Kinlaw WB, Quinn JL, Wells WA, Roser-Jones C, Moncur JT (2006). Spot 14: A marker of aggressive breast cancer and a potential therapeutic target. Endocrinology 147(9):4048-4055.

*Kinlaw WB, Scott SM, Maue RA, Memoli VA, Harris RD, Daniels GH, Porter DM, Belloni DR, Spooner ET, Ernesti MM, Noll WW (2005). Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 63(6):676-682.

Kisselev AF, Callard A, Goldberg AL (2006). Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281(13):8582-8590.

Kobayashi S, Lee SH, Meng XW, Mott JL, Bronk SF, Werneburg NW, Craig RW, Kaufmann SH, Gores GJ (2007). Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem 282(25):18407-18417.

Kolb A, Kleeff J, Arnold N, Giese NA, Giese T, Korc M, Friess H (2007). Expression and differential signaling of heregulins in pancreatic cancer cells. Int J Cancer 120(3):514-523.

Korc M (2005). Targeted therapeutics in pancreatic cancer: A ray of hope. Clin Cancer Res 11(1):410-411.

Koschmieder S, D'Alo F, Radomska H, Schoneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Sargin B, Kantarjian H, Andreeff M, Sporn MB, Perrotti D, Berdel WE, Muller-Tidow C, Serve H, Tenen DG (2007). CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood 110(10):3695-3705.

Layon ME, Ackley CJ, West RJ, Lowrey CH (2007). Expression of GATA-1 in a non-hematopoietic cell line induces beta-globin locus control region chromatin structure remodeling and an erythroid pattern of gene expression. J Mol Biol 366(3):737-744.

Le SB, Hailer MK, Buhrow S, Wang Q, Flatten K, Pediaditakis P, Bible KC, Lewis LD, Sausville EA, Pang YP, Ames MM, Lemasters JJ, Holmuhamedov EL, Kaufmann SH (2007). Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem 282(12):8860-8872.

Lee HK, Lewis LD, Tsongalis GJ, McMullin M, Schur BC, Wong SH, Yeo KT (2006). Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin Chim Acta 367(1-2):196-200.

Lee HK, Lewis LD, Tsongalis GJ, Schur BC, Jannetto PJ, Wong SH, Yeo KT (2007). Validation of a CYP2D6 genotyping panel on the NanoChip Molecular Biology Workstation. Clin Chem 53(5):823-828.

Levesque AA, Eastman A (2007). p53-based cancer therapies: Is defective p53 the Achilles Heel of the tumor? Carcinogenesis 28(1):13-20.

Levesque AA, Kohn EA, Bresnick E, Eastman A (2005). Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G(2) cell cycle checkpoints. Oncogene 24(23):3786-3796.

Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG, Otterson GA, Millard F, Ratain MJ (2007). A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 13(11):3302-3311.

*Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, Godwin AK, Wells W, DiRenzo J (2007). Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 67(2):501-510.

*Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, Sporn MB (2005). The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 65(11):4789-4798.

*Liby K, Honda T, Williams CR, Risingsong R, Royce DB, Suh N, Dinkova-Kostova AT, Stephenson KK, Talalay P, Sundararajan C, Gribble GW, Sporn MB (2007). Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities. Mol Cancer Ther 6(7):2113-2139.

*Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, Sporn MB (2007). The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 67(6):2414-2419.

*Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, Gribble GW, Sporn MB, Letterio JJ (2006). The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 12(14):4288-4293.

Liby KT, Yore MM, Sporn MB (2007). Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7(5):357-369.
Liu L, Li F, Cardelli JA, Martin KA, Blenis J, Huang S (2006). Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 25(53):7029-7040.

Liu Z, Neiss N, Zhou S, Henne-Bruns D, Korc M, Bachem M, Kornmann M (2007). Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth. Cancer Res 67(6):2712-2719.

*Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, Freemantle SJ, Dmitrovsky E (2007). Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A 104(10):4089-4094.

Mabaera R, Greene MR, Richardson CA, Conine SJ, Kozul CD, Lowrey CH (2007). Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin. Blood 111(1):411-420.

*Mabaera RH, Richardson CA, Johnson KJ, Hsu M, Fiering SH, Lowrey CH (2007). Developmental and differentiation-specific patterns of human {gamma} and {beta}-globin promoter DNA methylation. Blood 110(4):1343-1352.

Martel PM, Bingham CM, McGraw CJ, Baker CL, Morganelli PM, Meng ML, Armstrong JM, Moncur JT, Kinlaw WB (2006). S14 protein in breast cancer cells: Direct evidence of regulation by SREBP-1c, superinduction with progestin, and effects on cell growth. Exp Cell Res 312(3):278-288.

Matsushita A, Gotze T, Korc M (2007). Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res 67(21):10309-10316.

*McAllister TW, Ahles TA, Saykin AJ, FergusonRJ, McDonald BC, Lewis LD, Flashman LA, Rhodes CH (2004). Cognitive effects of cytotoxic cancer chemotherapy: Predisposing risk factors and potential treatments. Curr Psychiatry Rep 6(5):364-371.

Mesa C, Jr., Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA (2006). Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66(13):6521-6529.

Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalano-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ (2007). Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction:  CALGB 60101. J Clin Oncol 25(21):3055-3060.

Mita AC, Olszanski AJ, Walovitch RC, Perez RP, MacKay K, Tuck DP, Simmons C, Hammond S, Mita MM, Beeram M, Stone AJ, Rowinsky EK, Lewis LD (2007). Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel. Clin Cancer Res 13(11):3293-3301.

*Mix KS, Coon CI, Rosen ED, Suh N, Sporn MB, Brinckerhoff CE (2004). Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-delta(12,14) J2: A role for Smad signaling. Mol Pharmacol 65(2):309-318.

*Mulligan-Kehoe MJ, Schwartz GN, Zacharski LR (2006). The functions of plasminogen activator inhibitor-1: Do we have all the pieces of PAI? Thromb Res 117(5):483-486.

*North WG, Memoli VA, Keegan BP (2005). Immunohistochemical detection of NRSA on small cell lung cancer with a monoclonal antibody (MAG-1) that recognizes the carboxyl terminus of provasopressin. Appl Immunohistochem Mol Morphol 13(4):363-366.

*North WG, Wells W, Fay MJ, Mathew RS, Donnelly EM, Memoli VA (2003). Immunohistochemical evaluation of vasopressin expression in breast fibrocystic disease and ductal carcinoma in situ (DCIS). Endocr Pathol 14(3):257-262.

Ogden SK, Ascano M, Jr., Stegman MA, Robbins DJ (2004). Regulation of Hedgehog signaling: A complex story. Biochem Pharmacol 67(5):805-814.

Ogden SK, Casso DJ, Ascano M, Jr., Yore MM, Kornberg TB, Robbins DJ (2006). Smoothened regulates activator and repressor functions of Hedgehog signaling via two distinct mechanisms. J Biol Chem 281(11):7237-7243.

Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, Johnson DH, Rigas JR, Ding K, Shepherd FA (2007). Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 25(12):1553-1561.

*Peppercorn J, Herndon J, 2nd, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E (2005). Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: Results from Cancer and Leukemia Group B 9066. Cancer 104(8):1580-1589.

Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB (2006). HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24(19):3032-3038.

*Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, Beaulieu B, Ernstoff MS, Eastman A (2006). Modulation of cell cycle progression in human tumors: A pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 Inhibitor UCN-01 (NSC 638850). Clin Cancer Res 12(23):7079-7085.

*Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, Davis TH, Nugent WC, Memoli N, Hamilton M, Iwata KK, Rigas JR, Dmitrovsky E (2004). Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 10(22):7547-7554.

*Pipas JM, Barth RJ, Jr., Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, Cates JM, Ripple GH, Sutton JE, Gordon SR, McDonnell CE, Perez RP, Redfield N, Meyer LP, Marshall JF, Cole BF, Colacchio TA (2005). Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with ancreatic adenocarcinoma. Ann Surg Oncol 12(12):995-1004.

*Pipas JM, Meyer LP, Rhodes CH, Cromwell LD, McDonnell CE, Kingman LS, Rigas JR, Fadul CE (2005). A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol 71(3):301-305.

*Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, Gribble GW, Leesnitzer LM, Stimmel JB, Willson TM, Rosen E, Sporn MB (2003). The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 9(7):2798-2806.

Ramanathan RK, Fakih M, Mani S, Deutsch M, Perez RP, Ritter MA, Eiseman JL, Ivy SP, Trump DL, Belani CP, Parise RA, Potter DM, Egorin MJ (2006). Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemother Pharmacol 57(4):465-474.

Raymond L, Eck S, Hays E, Tomek I, Kantor S, Vincenti M (2007). RelA is required for IL-1beta stimulation of Matrix Metalloproteinase-1 expression in chondrocytes. Osteoarthritis Cartilage 15(4):431-441.

Raymond L, Eck S, Mollmark J, Hays E, Tomek I, Kantor S, Elliott S, Vincenti M (2006). Interleukin-1 beta induction of matrix metalloproteinase-1 transcription in chondrocytes requires ERK-dependent activation of CCAAT enhancer-binding protein-beta. J Cell Physiol 207(3):683-688.

*Rigas JR, Dragnev KH (2005). Emerging role of rexinoids in non-small cell lung cancer: Focus on bexarotene. Oncologist 10(1):22-33.

Rigas JR, Dragnev KH, Bubis JA (2005). Docetaxel in the treatment of esophageal cancer. Semin Oncol 32(2 Suppl 4):S39-S51.

Rigas JR, Kelly K (2007). Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol 2 Suppl 2:S77-S85.

Ripple MO, Kalmadi S, Eastman A (2005). Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival. Breast Cancer Res Treat 93(2):177-188.

Roach WG, Chavez JA, Miinea CP, Lienhard GE (2007). Substrate specificity and effect on GLUT4 translocation of the Rab GTPase-activating protein Tbc1d1. Biochem J 403(2):353-358.

Roy S, Eastman A, Gribble GW (2006). Synthesis of bisindolylmaleimides related to GF109203x and their efficient conversion to the bioactive indolocarbazoles. Org Biomol Chem 4(17):3228-3234.

Rzucidlo EM, Martin KA, Powell RJ (2007). Regulation of vascular smooth muscle cell differentiation. J Vasc Surg 45 Suppl A:A25-A32.

*Samudio I, Konopleva M, Hail N, Jr., Shi YX, McQueen T, Hsu T, Evans R, Honda T, Gribble GW, Sporn M, Gilbert HF, Safe S, Andreeff M (2005). 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J Biol Chem 280(43):36273-36282.

*Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli NJ, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R (2003). A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348(10):883-890.

*Shen J, Khan N, Lewis LD, Armand R, Grinberg O, Demidenko E, Swartz H (2003). Oxygen consumption rates and oxygen concentration in molt-4 cells and their mtDNA depleted (p0) mutants. Biophys J 84(2):1291-1298.

*Srinivasan S, Pogue BW, Carpenter C, Jiang S, Wells WA, Poplack SP, Kaufman PA, Paulsen KD (2007). Developments in quantitative oxygen-saturation imaging of breast tissue in vivo using multispectral near-infrared tomography. Antioxid Redox Signal 9(8):1143-1156.

*Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW, Sporn MB (2003). Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res 63(6):1371-1376.

Suh WS, Kim YS, Schimmer AD, Kitada S, Minden M, Andreeff M, Suh N, Sporn M, Reed JC (2003). Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia 17(11):2122-2129.

Tomlinson CR, Korc M (2006). Squeezing data from pancreatic juice. Cancer Biol Ther 5(10):1390-1391.

*Tretter CP, Lewis LD, Fisher J, Waugh MG, Ernstoff MS (2003). Taxanes synergize with the bispecific antibody MDXH447 to enhance antibody-dependent cell-mediated cytotoxicity. J Chemother 15(5):472-479.

van Swieten PF, Samuel E, Hernandez RO, van den Nieuwendijk AM, Leeuwenburgh MA, van der Marel GA, Kessler BM, Overkleeft HS, Kisselev AF (2007). A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome. Bioorg Med Chem Lett 17(12):3402-3405.

*Vincenti MP, Brinckerhoff CE (2007). Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: Can MMPs be good for you? J Cell Physiol 213(2):355-364.

Vrana JA, Cleaveland ES, Eastman A, Craig RW (2006). Inducer-and cell type-specific regulation of antiapoptotic MCL1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents. Apoptosis 11(8):1275-1288.

*Wells WA, Schwartz GN, Morganelli PM, Cole BF, Gibson JJ, Kinlaw WB (2006). Expression of "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer: Immunohistochemical analysis of a new molecular marker. Breast Cancer Res Treat 98(2):231-240.

White KA, Yore MM, Deng D, Spinella MJ (2005). Limiting effects of RIP140 in estrogen signaling: Potential mediation of anti-estrogenic effects of retinoic acid. J Biol Chem 280(9):7829-7834.

Wildi S, Kleeff J, Mayerle J, Zimmermann A, Bottinger EP, Wakefield L, Buchler MW, Friess H, Korc M (2007). Suppression of transforming growth factor beta signalling aborts caerulein induced pancreatitis and eliminates restricted stimulation at high caerulein concentrations. Gut 56(5):685-692.

*Wishart HA, Saykin AJ, McAllister TW, Rabin LA, McDonald BC, Flashman LA, Roth RM, Mamourian AC, Tsongalis GJ, Rhodes CH (2006). Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology 67(7):1221-1224.

*Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, Baumgartner KJ, Roebuck BD, Liby KT, Yore MM, Honda T, Gribble GW, Sporn MB, Kensler TW (2006). Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res 66(4):2488-2494.

Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, Kensler TW (2007). Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 6(1):154-162.

*Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB (2006). The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-{kappa}B activation through direct inhibition of I{kappa}B kinase {beta}. Mol Cancer Ther 5(12):3232-3239.

*Yuan Z, Goetz JA, Singh S, Ogden SK, Petty WJ, Black CC, Memoli VA, Dmitrovsky E, Robbins DJ (2007). Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene 26(7):1046-1055.

*Zarovnaya EL, Pallatroni HF, Hug EB, Ball PA, Cromwell LD, Pipas JM, Fadul CE, Meyer LP, Park JP, Biegel JA, Perry A, Rhodes CH (2007). Atypical teratoid/rhabdoid tumor of the spine in an adult: Case report and review of the literature. J Neurooncol 84(1):49-55.